



GP 164571
DfW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Aladar A. Szalay et al. Art Unit : 1645
Serial No. : 10/516,785 Examiner : Unknown
Filed : December 03, 2004 Confirm. No.: 7336
Customer No.: 20985
Title : Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


TRANSMITTAL LETTER

Dear Sir:

Transmitted herewith are a Supplemental Information Disclosure Statement, Forms PTO-1449 (9 pages), and copies of cited non US patent references for filing in connection with the above-identified application. Because this Supplemental Information Disclosure Statement is filed prior to receipt of a first office action on the merits in the above-referenced application, no fee is due. However, should it be determined that a fee for filing these papers is required, the Commissioner is authorized to charge Deposit Account No. 06-1050, as stated below:

☒ The Commissioner is hereby authorized to charge any fees that may be due in connection with this paper or with this application during its entire pendency to Deposit Account No. 06-1050. A duplicate of this sheet is enclosed.

Respectfully submitted,



Stephanie L. Seidman
Reg. No. 33,779

Dated: July 25, 2005
Attorney Docket No. 17248-004US1 / 4804US
Address all correspondence to:
Stephanie L. Seidman
Fish & Richardson P.C.
12390 El Camino Real
San Diego, California 92130
Telephone: (858) 678-4777
Facsimile: (202) 626-7796
Email: seidman@fr.com


Applicant : Aladar A. Szalay et al.
Serial No. : 10/516,785
Filed : December 03, 2004
Supplemental Information Disclosure Statement
Page : 2 of 2

Attorney's Docket No.: 17248-004US1 / 4804US

not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. 1.56(b) exists.

Applicant respectfully requests that the Examiner review the foregoing references and they be made of record in the file history of the above-captioned application.

Respectfully submitted,



Stephanie L. Seidman
Reg. No. 33,779

Dated: July 25, 2005
Attorney Docket No. 17248-004US1 / 4804US
Address all correspondence to:
Stephanie L. Seidman
Fish & Richardson P.C.
12390 El Camino Real
San Diego, California 92130
Telephone: (858) 678-4777
Facsimile: (202) 626-7796
Email: seidman@fr.com

JUL 26 2005

Sheet 1 of 9

Substitute Form PTO-1449 (Rev. 01-01-03) List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 17248-004US1 / 4804US	Application No. 10/516,785
	Applicant Szalay et al.			
	Filing Date December 3, 2004		Group Art Unit Unassigned	

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	2003/0009015	01/09/03	Ulrich et al.	536	23.1	06/25/97
	AB	2003/0031681	02/13/03	Mc Cart et al.	424	186.1	11/13/01
	AC	2003/0086906	05/08/03	Mastrangelo et al.	424	93.2	11/04/02
	AD	2003/0165465	09/04/03	Roberts et al.	424	93.2	06/13/02
	AE	2003/0198627	10/23/03	Arts et al.	424	93.21	08/23/02
	AF	2003/0228330	12/11/03	Falkner et al.	424	232.1	03/14/03
	AG	4,722,848	02/02/88	Paoletti et al.	424	199.1	06/19/84
	AH	5,693,533	12/02/97	Raney et al.	435	366	12/07/94
	AI	5,718,902	02/17/98	Yilma et al.	424	211.1	06/17/91
	AJ	5,830,702	11/03/98	Portnoy et al.	435	69.3	12/30/94
	AK	6,093,700	07/25/00	Mastrangelo et al.	514	44	02/20/97
	AL	6,190,657	02/20/01	Pawelek et al.	424	93.1	06/04/96
	AM	6,428,968	08/06/02	Molnar-Kimber et al.	435	7.23	11/08/99
	AN	6,455,673	09/24/02	Collier	530	350	02/16/99
	AO	6,548,068	04/15/03	Schlom et al.	424	199.1	01/07/00
	AP	6,596,279	07/22/03	Paoletti et al.	424	199.1	08/14/98
	AQ	6,627,160	09/03/03	Wold et al.	424	93.2	09/19/01
	AR	6,685,935	02/03/04	Pawelek et al.	424	93.2	07/21/99


Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AS	0 037 441	10/14/81	EP, A1				
	AT	0 037 441	05/09/84	EP, B1				
	AU	03/045153	06/05/03	PCT A1				
	AV	03/102168	12/11/03	PCT A1				
	AW	1 281 777	02/05/03	EP A1				
	AX	99/32646	07/01/99	PCT				

Examiner Signature

Date Considered


EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




Substitute Form TO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))	Attorney's Docket No. 17248-004US1 / 4804US	Application No. 10/516,785
	Applicant Szalay et al.	
	Filing Date December 3, 2004	Group Art Unit Unassigned

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AY	"Generation of Recombinant Vaccinia Viruses," Unit 16.17 in <i>Short Protocols in Molecular Biology 2nd edition: a compendium of Methods from Current Protocols in Molecular Biology</i> , Green Publishing and Wiley-Interscience Supplement 15:16.71-16.82 (1992)
	AZ	Adonai <i>et al.</i> , "Ex vivo cell labeling with ⁶⁴ Cu-pyruvaldehyde-bis(N ⁴ -methylthiosemicarbazone) for imaging cell trafficking in mice with positron-emission tomography," <i>Proc. Natl. Acad. Sci. USA</i> 99: 3030-3035 (2002)
	BA	Altschul <i>et al.</i> , "Basic local alignment search tool," <i>J Molec Biol</i> 215:403-410 (1990)
	BB	Ando, N. and M. Matumoto, "Unmasking of growth of dermovaccinia strain dairen I in L cells by acid treatment of cells after virus adsorption," <i>Japan. J. Microbiol.</i> 14(3): 181-186 (1979)
	BC	Antoine <i>et al.</i> , "The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses," <i>Virology</i> 244: 365-396 (1998)
	BD	ATCC Accession No. 59324
	BE	ATCC Accession No. 59325
	BF	ATCC Accession Nos. CCL-121
	BG	ATCC Accession Nos. CRL-12011
	BH	ATCC Accession Nos. CRL-12012
	BI	ATCC catalog no. 700294
	BJ	ATCC No. CCL-107
	BK	ATCC No. CRL-6475
	BL	ATCC under Accession number: VR-1549
	BM	Barrett <i>et al.</i> , "Yellow Fever Vaccines," <i>Biologicals</i> 25:17-25 (1997)
	BN	Bauerschnitz <i>et al.</i> , "Treatment of Ovarian Cancer with a Tropism Modified Oncolytic Adenovirus," <i>Cancer Research</i> 62: 1266-1270 (2002)
	BO	Benes <i>et al.</i> , "M13 and pUC vectors with new unique restriction sites for cloning," <i>Gene</i> 130: 151-152 (1993)
	BP	Bernards <i>et al.</i> , "Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector," <i>Proc. Natl. Acad. Sci. USA</i> 84: 6854-6858 (1987)
	BQ	Beshara <i>et al.</i> , "Kinetic analysis of ⁵² Fe-labelled iron(III) hydroxide-sucrose complex following blous administration using positron emission tomography," <i>Br. J. Haematol.</i> 104: 288-295 (1999)
	BR	Beshara <i>et al.</i> , "Pharmacokinetics and red cell utilization of iron(III) hydroxide-sucrose complex in anaemic patients: a study using positron emission tomography," <i>Br. J. Haematol.</i> 104: 296-302 (1999)
	BS	Bisno <i>et al.</i> , "Streptococcal infections of skin and soft tissues," <i>N. Engl. J. Med.</i> 334(4): 240-245 (1996)

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

 Substitute Form PTO-449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17248-004US1 / 4804US	Application No. 10/516,785
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))			Applicant Szalay et al.	
			Filing Date December 3, 2004	Group Art Unit Unassigned
Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner Initial	Desig. ID	Document		
	BT	Blakemore, "Magnetotactic Bacteria," Annu. Rev. Microbiol. 36: 217-238 (1982)		
	BU	Broder, C.C. and P.L. Earl, "Recombinant Vaccinia Viruses," Mol. Biotechnol. 13: 223-245 (1999)		
	BV	Brouqui, P. and D. Raoult, "Endocarditis due to rare and fastidious bacteria," Clinical Microbiology Reviews 14(1): 177-207 (2001)		
	BW	Calonder <i>et al.</i> , "Kinetic modeling of $^{52}\text{Fe}/^{52\text{m}}\text{Mn}$ -Citrate at the Blood-Brain Barrier by Positron Emission Tomography," J. Neurochem. 73: 2047-2055 (1999)		
	BX	Carrillo and Lipman <i>et al.</i> , "The Multiple Sequence Alignment Problem in Biology," SIAM J Applied Math 48:1073-1082 (1988)		
	BY	Chakrabarti <i>et al.</i> , "Vaccinia virus expression vector: coexpression of β -galactosidase provides visual screening of recombinant virus plaques," Mol. Cell Biol. 5:3403-3409 (1985)		
	BZ	Chakrabarti <i>et al.</i> , "Compact, Synthetic, Vaccinia Virus Early/Late Promoter for Protein Expression," BioTechniques 23(6): 1094-1097 (1997)		
	CA	Chamberlain <i>et al.</i> , "Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines," Cancer Res. 56: 2832-2836 (1996)		
	CB	Child <i>et al.</i> , "Insertional inactivation of the large subunit of ribonucleotide reductase encoded by vaccinia virus is associated with reduced virulence <i>in vivo</i> ," Virology 174:625-629 (1990)		
	CC	Colinas <i>et al.</i> , "A DNA ligase gene in the copenhagen strain of vaccinia virus is nonessential for viral replication and recombination," Virology 179: 267-275 (1990)		
	CD	Cusumano <i>et al.</i> , "Synergic activities of streptococcal pyrogenic exotoxin A and lipoteichoic acid in cytokine induction," Microbiologica 23(1): 37-45 (2000)		
	CE	Davison, A. J. and B. Moss, "Structure of Vaccinia Virus Early Promoters," J. Mol. Biol. 210: 749-769 (1989)		
	CF	Davison <i>et al.</i> , "New vaccinia virus recombination plasmids incorporating a synthetic late promoter for high level expression of foreign proteins," Nucleic Acids Research 18: 4285-4286 (1990)		
	CG	Devereux, J., <i>et al.</i> , "A comprehensive set of sequence analysis programs for the VAX," Nucleic Acids Research 12(1): 387-95 (1984)		
	CH	Earl <i>et al.</i> , "T-Lymphocyte Priming and Protection Against Friend Leukemia by Vaccinia-Retrovirus <i>env</i> Gene Recombinant," Science 234: 728-731 (1986)		
	CI	Ebert <i>et al.</i> , "Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats," Cancer Research 63: 3605-3611 (2003)		
	CJ	Ebert <i>et al.</i> , "Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer," Cancer Research 64: 3265-3270 (2004)		
	CK	Estin <i>et al.</i> , "Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy," Proc. Natl. Acad. Sci. USA 85: 1052-1056 (1988)		
	CL	Ferretti <i>et al.</i> , "Complete genome sequence of an M1 strain of <i>Streptococcus pyogenes</i> ," Proc. Natl. Acad. Sci. USA 98(8): 4658-4663 (2001)		
	CM	Flexner <i>et al.</i> , "Successful vaccination with a polyvalent live vector despite existing immunity to an expressed antigen," Nature 355:259-262 (1988)		
	CN	Flexner <i>et al.</i> , "Characterization of Human Immunodeficiency Virus <i>gag/pol</i> Gene Products Expressed by Recombinant Vaccinia Viruses," Virology 166: 339-349 (1988)		

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449
(Modified)U.S. Department of Commerce
Patent and Trademark OfficeAttorney's Docket No.
17248-004US1 /
4804USApplication No.
10/516,785**List of Patents and Publications for Applicant's
Information Disclosure Statement**

(37 CFR §1.98(b))


Applicant
Szalay et al.Filing Date
December 3, 2004Group Art Unit
Unassigned**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	CO	Giedlin et al., "Vesicular stomatitis virus: an exciting new therapeutic oncolytic virus candidate for cancer or just another chapter from <i>Field's Virology</i> ?" <i>Cancer Cell</i> 4: 241-243 (2003)
	CP	Goebel et al., "The complete DNA sequence of vaccinia virus," <i>Virology</i> 179:247-266 (1990)
	CQ	Goebel et al., "Appendix to 'The complete DNA Sequence of Vaccinia Virus,'" <i>Virology</i> 179: 517-563 (1990)
	CR	Green et al., "Necrotizing Fasciitis," <i>Chest</i> 110(1):219-229 (1996)
	CS	Greinwald et al., "Treatment of lymphangiomas in children: an update of Picibanil (Ok-432) sclerotherapy," <i>Otolaryngol Head Neck Surg</i> 121(4): 381-387 (1999)
	CT	Gribskov et al., "Sigma factors from <i>E. coli</i> , <i>B. subtilis</i> , phage SP01, and phage T4 are homologous proteins," <i>Nucl. Acids Res.</i> 14:6745-6763 (1986)
	CU	Huang et al., "Oncolysis of hepatic metastasis of colorectal cancer by recombinant vesicular stomatitis virus in immune-competent mice," <i>Mol. Ther.</i> 8(3): 434-440 (2003)
	CV	Hurst et al., "A novel model of a metastatic human breast tumour xenograft line," <i>Br. J. Cancer</i> 68: 274-276 (1993)
	CW	Isaacs et al., "Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence," <i>Proc Natl Acad Sci U S A.</i> 89:628-632 (1992)
	CX	Johnson et al., "An update on the vaccinia virus genome," <i>Virology</i> 196: 381-401 (1993)
	CY	Kantor et al., "Antitumor Activity and Immune Responses Induced by a Recombinant Carcinoembryonic Antigen-Vaccinia Virus Vaccine," <i>J. Natl. Cancer Inst.</i> 84: 1084-1091 (1992)
	CZ	Katz et al., "Mutations in the vaccinia virus A33R and B5R envelope proteins that enhance release of extracellular virions and eliminate formation of actin-containing microvilli without preventing tyrosine phosphorylation of the A36R protein," <i>J. Virology</i> 77:12266-12275 (2003)
	DA	Kotwal et al., "Mapping and Insertional Mutagenesis of a Vaccinia Virus Gene Encoding a 13, 800-Da Secreted Protein," <i>Virology</i> 171:579-587 (1989)
	DB	Kozak, M., "Structural features in Eukaryotic mRNAs that modulate the Initiation of Translation," <i>J. Biol. Chem.</i> 266:19867-19870 (1991)
	DC	Lamberton et al., "Construction and characterization of a bioluminescent <i>Streptococcus pyogenes</i> ," <i>Proceedings of the 12th International Symposium on Bioluminescence and Chemiluminescence</i> Progress & Current Applications, Stanley, P.E. and L.J. Kricka et al. (Eds). World Scientific Publishing Co. Pte. Ltd., pp 85-88 (2002)
	DD	Lamberton et al., "Generation and characterization of a bioluminescent <i>Streptococcus pyogenes</i> ," <i>Proceedings of the 12th International Symposium on Bioluminescence & Chemiluminescence: 5-9 April 2002, Robinson College, University of Cambridge, UK</i> , p 3.22 (2002)
	DE	Lathe et al., "Tumour prevention and rejection with recombinant vaccinia," <i>Nature (London)</i> 326: 878-880 (1987)
	DF	Lee et al. "Prodrug and antedrug: two diametrical approaches in designing safer drugs," <i>Arch. Pharm. Res.</i> 25(2): 111-136 (2002)
	DG	Lee et al., "Molecular attenuation of vaccinia virus: mutant generation and animal characterization," <i>Journal of Virology</i> 66:2617-2630 (1992)

Examiner Signature

Date Considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PT-1449
(Modified)U.S. Department of Commerce
Patent and Trademark OfficeAttorney's Docket No.
17248-004US1 /
4804USApplication No.
10/516,785**List of Patents and Publications for Applicant's
Information Disclosure Statement**

(37 CFR §1.98(b))


Applicant
Szalay et al.Filing Date
December 3, 2004Group Art Unit
Unassigned**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	DH	Leenders <i>et al.</i> , "Blood to brain iron uptake in one Rhesus monkey using [Fe-52]-citrate and positron emission tomography (PET): influence of haloperidol," J. Neural. Transm. Suppl. 43: 123-132 (1994)
	DI	Lemmon <i>et al.</i> , "Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment," Gene Therapy 4: 791-796 (1997)
	DJ	Lemmon <i>et al.</i> , "Anaerobic bacteria as a gene delivery system to tumors," Proceedings of the 85th Annual Meeting of the American Association for Cancer Research, San Francisco, CA April 10-13, 1994, published in: Proc. Am. Cancer Research Assn 35: 374 (1994)
	DK	Lewis <i>et al.</i> , "Comparison of Four ⁶⁴ Cu-Labeled Somatostatin Analogues in Vitro and in a Tumor-Bearing Rat Model: Evaluation of New Derivatives for Positron Emission Tomography Imaging and Targeted Radiotherapy," J. Med. Chem. 42: 1341-1347 (1999)
	DL	Li <i>et al.</i> , " <i>Bifidobacterium adolescentis</i> as a delivery system of endostatin for cancer gene therapy: Selective Inhibitor of angiogenesis and hypoxic tumor growth," Cancer Gene Therapy 10: 105-111 (2003)
	DM	Liau <i>et al.</i> , "Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens," J. Neurosurg. 90(6): 1115-1124 (1999)
	DN	Liu <i>et al.</i> , "An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency," Molecular Therapy 9(6): 786-803 (2004)
	DO	Lopez <i>et al.</i> , "Infections in children with malignant disease in Argentina," Cancer 47(5): 1023-1030 (1981)
	DP	Mayford <i>et al.</i> , "CaMKII Regulates the Frequency-Response Function of Hippocampal Synapses for the Production of Both LTD and LTP," Cell 81: 891-904 (1995)
	DQ	Mayr <i>et al.</i> , "The Smallpox Vaccination Strain MVA: Marker, Genetic Structure, Experience Gained with the Parenteral Vaccination and Behavior in Organisms with a Debilitated Defense Mechanism," Zentbl. Bakteriол. Hyg. Abt. 1 Orig. B 167: 375-390 (1978) [In German, English abstract on first page of article]
	DR	McAllister <i>et al.</i> , "Recombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastases," J. Virol. 74:9197-9205 (2000).
	DS	McAneny <i>et al.</i> , "Results of a Phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer," Ann. Surg. Oncol. 3(5): 495-500 (1996)
	DT	Mikryukov <i>et al.</i> , "Structural-functional organization of segment of vaccinia virus genome," Soviet Biotechnology (Biotekhnologiya) 4: 19-25 (1988) [corresponds to pages 442-449 in the Russian language edition]
	DU	Moore <i>et al.</i> , "Steroid hormone synthesis by a vaccinia enzyme: a new type of virus virulence factor," EMBO J. 1992 11:1973-1980, corrigendum in The EMBO Journal 11(9): 3490 (1992)
	DV	Moss, B., "Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety," Proc. Natl. Acad. Sci. USA 93: 11341-11348 (1996)
	DW	Moss, B., "Poxvirus vectors: cytoplasmic expression of transferred genes," Curr. Opin. Genet. Dev. 3: 86-90 (1993)


Examiner Signature

Date Considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute Form PTO-1449 (Modified 8/01)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 17248-004US1 / 4804US	Application No. 10/516,785
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))				Applicant Szalay et al.	
				Filing Date December 3, 2004	Group Art Unit Unassigned
Other Documents (include Author, Title, Date, and Place of Publication)					
Examiner Initial	Desig. ID	Document			
	DX	Mullen et al., "Viral Oncolysis," The Oncologist 7: 106-119 (2002)			
	DY	Mulryan et al., "Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors," Mol Cancer Ther 1(12): 1129-1137 (2002)			
	DZ	Munagala et al., "The purine nucleoside phosphorylase from <i>Trichomonas vaginalis</i> is a homologue of the bacterial enzyme," Biochemistry 41(33): 10382-10389 (2002)			
	EA	NCBI Protein AAA48282			
	EB	NCBI Nucleotide AF012825			
	EC	NCBI Nucleotide. AF095689			
	ED	NCBI Nucleotide AF380138			
	EE	NCBI Nucleotide AX003206			
	EF	NCBI Nucleotide. AY009089			
	EG	NCBI Nucleotide AY243312			
	EH	NCBI Nucleotide AY484669			
	EI	NCBI Nucleotide AY603355			
	EJ	NCBI Nucleotide M35027			
	EK	NCBI Nucleotide M57977			
	EL	NCBI Nucleotide U94848			
	EM	NCBI Nucleotide X69198			
	EN	NCBI Nucleotide X94355			
	EO	Needleman et al., "A general method applicable to the search for similarities in the amino acid sequences of two proteins," J. Mol. Biol. 48:443-453 (1970)			
	EP	Nogrady, T., <i>Medicinal Chemistry A Biochemical Approach</i> , New York: Oxford University Press, pages 388-392 (1985)			
	EQ	Oertli et al., "Non-replicating recombinant vaccinia virus encoding murine B-7 molecules effective costimulation of naive CD4 ⁺ splenocytes <i>in vitro</i> ," J. Gen. Virol. 77: 3121-3125 (1996)			
	ER	Okamoto et al., "Severe impairment of anti-cancer effect of lipoteichoic acid-related molecule isolated from a penicillin-killed <i>Streptococcus pyogenes</i> in toll-like receptor 4-deficient mice," International Immunopharmacology 1(9-10): 1789-1795 (2001)			
	ES	Patel et al., "A poxvirus-derived vector that directs high levels of expression of cloned genes in mammalian cells," Proc. Natl. Acad. Sci. USA 85: 9431-9435 (1988)			
	ET	Pawelek et al., "Tumor-targeted <i>Salmonella</i> as a Novel Anticancer Vector," Cancer Therapy 57: 4537-4544 (1997)			
Examiner Signature			Date Considered		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17248-004US1 / 4804US	Application No. 10/516,785
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))		Applicant Szalay et al.	
		Filing Date December 3, 2004	Group Art Unit Unassigned

Other Documents (include Author, Title, Date, and Place of Publication)


Examiner Initial	Desig. ID	Document
	EU	Pearson <i>et al.</i> , "Improved tools for biological sequence comparison," Proc. Natl. Acad. Sci. USA 85:2444-2448 (1988)
	EV	Pilcher, H., "GM Bug activates cancer drug: Bacteria targets medicine to shrivel mouse tumours," news @ nature.com, Published online: 22 April 2004; http://www.nature.com/news/2004/040419/full/040419-9.html , (accessed on November 18, 2004)
	EW	Pinkert <i>et al.</i> , "An albumin enhancer located 10 kb upstream functions along with its promoter to direct efficient, liver-specific expression in transgenic mice," Genes & Dev. 1: 268-76 (1987)
	EX	Plucienniczak <i>et al.</i> , "Nucleotide sequence of a cluster and late genes in a conserved segment of the vaccinia virus genome," Nucleic Acids Research 13(3): 993-998 (1985)
	EY	Puhlmann <i>et al.</i> , "Vaccinia virus as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant," Cancer Gene Therapy 7(1): 66-73 (2000)
	EZ	Qin, H. and S.K. Chatterjee, "Cancer gene therapy using tumor cells infected with recombinant vaccinia virus expressing GM-CSF," Human Gene Ther. 7: 1853-1860 (1996)
	FA	Rao <i>et al.</i> , "IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines," J. Immunol. 156: 3357-3365 (1996)
	FB	Rodriguez <i>et al.</i> , "Highly attenuated vaccinia virus mutants for the generation of safe recombinant viruses," Proc. Natl. Acad. Sci. USA 86: 1287-1291 (1989)
	FC	Rolston <i>et al.</i> , "In vitro activity of LY264826, a new glycopeptide antibiotic, against gram-positive bacteria isolated from patients in cancer," Antimicrob. Agents Chemother. 34(11):2137-2141 (1990)
	FD	Roseman <i>et al.</i> , "The vaccinia virus HindIII fragment: nucleotide sequence of the left 6.2kb," Virology 178: 410-418 (1990)
	FE	Roth <i>et al.</i> , "p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge," Proc. Natl. Acad. Sci. USA 93: 4781-4786 (1996)
	FF	Schwartz and Dayhoff, eds., ATLAS OF PROTEIN SEQUENCE AND STRUCTURE, National Biomedical Research Foundation, pp. 353-358 (1979)
	FG	Shilo, B. and R.A. Weinberg, "DNA sequences homologous to vertebrate oncogenes are conserved in <i>Drosophila melanogaster</i> ," Proc. Natl. Acad. Sci. USA 78:6789-6792 (1981)
	FH	Shinozaki <i>et al.</i> , "Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus," Mol. Ther. 9(3): 368-376 (2004)
	FI	Silva <i>et al.</i> , "Cloning, overexpression, and purification of functional human purine nucleoside phosphorylase," Protein Expr. Purif. 27(1): 158-164 (2003)
	FJ	Smith, T.F. and M.S. Waterman, "Comparison of biosequences," Adv. Appl. Math. 2:482-489 (1981)
	FK	Sorscher <i>et al.</i> , "Tumor cell bystander killing in colonic carcinoma utilizing the <i>Escherichia coli</i> <i>DeoD</i> gene to generate toxic purines," Gene Therapy 1(4): 233-238 (1994)
	FL	Stevens, D.L., "Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment," Emerg. Infect. Dis. 1(3): 69-78 (1995)
	FM	Sugimoto, M. and K. Yamanouchi, "Characteristics of an attenuated vaccinia virus strain, LC16m0, and its recombinant virus vaccines," Vaccine 12(8): 675-681 (1994)
	FN	Sugimoto <i>et al.</i> , "Gene structures of low-neurovirulent vaccinia virus LC16m0, LC16m8, and their Lister Original (LO) strains," Microbial. Immunol. 29: 421-428 (1985)

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Substitute Form PTO-1449 (Modified) PATENT & TRADEMARK OFFICE		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17248-004US1 / 4804US	Application No. 10/516,785
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))			Applicant Szalay et al.	
			Filing Date December 3, 2004	Group Art Unit Unassigned
Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner Initial	Desig. ID	Document		
	FO	Suvorov et al., "Physical and genetic chromosomal map of an M type 1 strain of <i>Streptococcus pyogenes</i> ," J. Bacteriol. 178(18): 5546-5549 (1996)		
	FP	Suzuki et al., "Management of orbital lymphangioma using intralesional injection of OK-432," Br. J. Ophthalmol. 84(6): 614-617 (2000)		
	FQ	Sze et al., "Dr. Gary J. Becker Young Investigator Award: intraarterial adenovirus for metastatic gastrointestinal cancer: activity, radiographic response, and survival," J. Vasc. Interv. Radiol. 14(3): 279-290 (2003)		
	FR	Takahashi-Nishimaki et al., "Genetic analysis of vaccinia virus Lister strain and its attenuated mutant LC16m8: production of intermediate variants by homologous recombination," J. Gen. Virol. 68: 2705-2710 (1987)		
	FS	Theys et al., "Tumor-specific gene delivery using genetically engineered bacteria," Curr Gene Ther 3(3): 207-221 (2003)		
	FT	Timiriasova et al., "[Analysis of reporter gene expression at different segments of the vaccinia virus genome]," Mol. Biol. (Mosk.) 27(2): 392-401 (1993) [article in Russian, English abstract on last page of article]		
	FU	Timiryasova et al., "Construction of recombinant vaccinia viruses using PUV-inactivated virus as a helper," BioTechniques 31: 534-540 (2001)		
	FV	Toth et al., "An oncolytic adenovirus vector combining enhanced cell-to-cell spreading, mediated by the ADP cytolytic protein, with selective replication in cancer cells with deregulated <i>Wnt</i> signaling," Cancer Research 64: 3638-3644 (2004)		
	FW	Tsung et al., "Gene expression and cytopathic effect of vaccinia virus inactivated by psoralen and long-wave UV light," J. Virol. 70: 165-171 (1996)		
	FX	Umphress et al., "Vaccinia virus mediated expression of human APC induces apoptosis in colon cancer cells," Transgenics 4:19-33 (2003)		
	FY	Veijola et al., "Cloning, Baculovirus Expression, and Characterization of the α Subunit of Prolyl 4-Hydroxylase from the nematode <i>Caenorhabditis elegans</i> ," J. Biol. Chem. 269: 26746-26753 (1994)		
	FZ	Vidal et al., "Tissue-specific control elements of the Thy-1 gene," EMBO J. 9(3): 833-840 (1990)		
	GA	Watson et al. Molecular Biology of the Gene, 4th Edition, 1987, The Benjamin/Cummings Pub. co., p.224		
	GB	Wolffe et al., "Deletion of the vaccinia virus B5R gene encoding a 42-kilodalton membrane glycoprotein inhibits extracellular virus envelope formation and dissemination," Journal of Virology 67(8): 4732-4741 (1993) and erratum in Journal of Virology, vol. 67, pp5709-5711 (1993)		
	GC	Wu et al., "High resolution microPET imaging of carcino-embryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment," PNAS USA 97(15): 8495-8500 (2000)		
	GD	Yang et al., "Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases," Proc. Natl. Acad. Sci. USA 97(3):1206-1211 (2000)		
	GE	Yang et al., "Effects of growth medium composition, iron sources and atmospheric oxygen concentrations on production of luciferase-bacterial magnetic particle complex by a recombinant <i>Magnetospirillum magneticum</i> AMB-1," Enzyme Microb. Technol. 29: 13-19 (2001)		
	GF	Yazawa et al., "Current progress in suicide gene therapy for cancer," World J. Surg 26(7): 783-789 (2002)		

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

 Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 17248-004US1 / 4804US	Application No. 10/516,785
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))				Applicant Szalay et al.	
				Filing Date December 3, 2004	Group Art Unit Unassigned
Other Documents (include Author, Title, Date, and Place of Publication)					
Examiner Initial	Desig. ID	Document			
	GG	Yoshida et al., "Cell growth-inhibitory action of SAGP, an antitumor glycoprotein from <i>Streptococcus pyogenes</i> (Su strain)," Jpn. J. Pharmacol. 45(2): 143-147 (1987)			
	GH	Yoshida et al., "Characterization of a streptococcal antitumor glycoprotein (SAGP)," Life Sciences 62(12): 1043-1053 (1998)			
.	GI	Yoshida et al., "Growth-inhibitory effect of streptococcal antitumor glycoprotein on human epidermoid carcinoma A431 cells: involvement of dephosphorylation of epidermal growth factor receptor," Cancer Research 61(16): 6151-6157 (2001)			
.	GJ	Zimmermann <i>et al.</i> , "Independent regulatory elements in the nestin gene direct transgene expression to neural stem cells," Neuron 12: 11-24 (1994)			
	GK	Zolotukhin <i>et al.</i> , "A 'Humanized' Green Fluorescent Protein cDNA adapted for high-level expression in mammalian cells," J. Virol. 70:4646-4654 (1996)			

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	